Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
Anavex Life Sciences (Nasdaq: AVXL) has announced its participation in the 45th Annual TD Cowen Health Care Conference, taking place March 3-5, 2025, at the Boston Marriott Copley Place. Christopher U Missling, President & Chief Executive Officer, will present on Monday, March 3rd, 2025, at 9:50 AM ET.
The clinical-stage biopharmaceutical company, which focuses on developing innovative treatments for neurological conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome, will provide a live audio webcast of the presentation through their website's Investors section. An archived version will be made available later the same day.
Anavex Life Sciences (Nasdaq: AVXL) ha annunciato la sua partecipazione alla 45a Conferenza Annuale TD Cowen sulla Salute, che si svolgerà dal 3 al 5 marzo 2025, presso il Boston Marriott Copley Place. Christopher U Missling, Presidente e Amministratore Delegato, presenterà lunedì 3 marzo 2025, alle 9:50 AM ET.
La società biofarmaceutica in fase clinica, che si concentra sullo sviluppo di trattamenti innovativi per condizioni neurologiche come il morbo di Alzheimer, il morbo di Parkinson, la schizofrenia e la sindrome di Rett, fornirà una trasmissione audio in diretta della presentazione attraverso la sezione Investitori del loro sito web. Una versione archiviata sarà resa disponibile più tardi nella stessa giornata.
Anavex Life Sciences (Nasdaq: AVXL) ha anunciado su participación en la 45ª Conferencia Anual de Salud TD Cowen, que tendrá lugar del 3 al 5 de marzo de 2025, en el Boston Marriott Copley Place. Christopher U Missling, Presidente y Director Ejecutivo, presentará el lunes 3 de marzo de 2025, a las 9:50 AM ET.
La compañía biofarmacéutica en etapa clínica, que se centra en desarrollar tratamientos innovadores para condiciones neurológicas como la enfermedad de Alzheimer, la enfermedad de Parkinson, la esquizofrenia y el síndrome de Rett, ofrecerá una transmisión de audio en vivo de la presentación a través de la sección de Inversores de su sitio web. Una versión archivada estará disponible más tarde ese mismo día.
Anavex Life Sciences (Nasdaq: AVXL)는 제45회 TD Cowen 건강 관리 회의에 참가할 것이라고 발표했습니다. 이 회의는 2025년 3월 3일부터 5일까지 보스턴 메리어트 코플리 플레이스에서 열립니다. Christopher U Missling 사장 겸 CEO는 2025년 3월 3일 월요일 오전 9시 50분 ET에 발표할 예정입니다.
신경학적 질환, 즉 알츠하이머병, 파킨슨병, 정신분열증 및 레트 증후군에 대한 혁신적인 치료법 개발에 중점을 둔 임상 단계의 생물제약 회사는 발표의 라이브 오디오 웹캐스트를 웹사이트의 투자자 섹션을 통해 제공할 것입니다. 당일 오후에 아카이브된 버전이 제공될 예정입니다.
Anavex Life Sciences (Nasdaq: AVXL) a annoncé sa participation à la 45e Conférence Annuelle TD Cowen sur la Santé, qui se déroulera du 3 au 5 mars 2025, au Boston Marriott Copley Place. Christopher U Missling, Président et Directeur Général, présentera le lundi 3 mars 2025, à 9h50 ET.
L'entreprise biopharmaceutique en phase clinique, qui se concentre sur le développement de traitements innovants pour des affections neurologiques telles que la maladie d'Alzheimer, la maladie de Parkinson, la schizophrénie et le syndrome de Rett, proposera une diffusion audio en direct de la présentation via la section Investisseurs de son site web. Une version archivée sera disponible plus tard dans la journée.
Anavex Life Sciences (Nasdaq: AVXL) hat seine Teilnahme an der 45. jährlichen TD Cowen Gesundheitskonferenz bekannt gegeben, die vom 3. bis 5. März 2025 im Boston Marriott Copley Place stattfindet. Christopher U Missling, Präsident und CEO, wird am Montag, den 3. März 2025, um 9:50 Uhr ET präsentieren.
Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Behandlungen für neurologische Erkrankungen wie Alzheimer, Parkinson, Schizophrenie und das Rett-Syndrom konzentriert, wird eine Live-Audioübertragung der Präsentation über den Investor-Bereich seiner Website bereitstellen. Eine archivierte Version wird später am selben Tag verfügbar sein.
- None.
- None.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025. Christopher U Missling, PhD, President & Chief Executive Officer, will present the Company in a session scheduled at 9:50 AM (ET) on Monday, March 3rd, 2025, at the Boston Marriott Copley Place in Boston, MA.
A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
When is Anavex (AVXL) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch AVXL's presentation at the TD Cowen Conference?
What medical conditions is AVXL currently developing treatments for?
Where will the 45th Annual TD Cowen Health Care Conference featuring AVXL be held?
